Epizyme Misses Q1 EPS by 3c
- ByInvesting.com-
Epizyme (NASDAQ:EPZM) reported Q1 EPS of ($0.38), $0.03 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $8.7 million versus the consensus estimate of...
Symbol | Exchange | Currency |
|---|
Epizyme (NASDAQ:EPZM) reported Q1 EPS of ($0.38), $0.03 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $8.7 million versus the consensus estimate of...
Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Consumer Goods, Financials and Technology sectors led shares lower. At the close in NYSE, the...
Barclays (LON:BARC) analyst Peter Lawson maintained a Buy rating on Epizyme (NASDAQ:EPZM) on Tuesday, setting a price target of $17, which is approximately 63.30% above the...
Epizyme Inc. (NASDAQ:EPZM) incurred a loss of 59 cents per share in fourth-quarter 2019, wider than the Zacks Consensus Estimate of a loss of 51 cents and the year-ago loss of...
Investors in Epizyme, Inc. (NASDAQ:EPZM) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 20, 2020 $35.00 Call had...
It was a ho-hum week for the biotech sector with Incyte (NASDAQ:INCY) coming out with strong results for the fourth quarter, and pipeline and regulatory updates from a few small...
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Sell | Sell | Strong Sell |
| Technical Indicators | Strong Sell | Sell | Buy | Strong Sell | Strong Sell |
| Summary | Strong Sell | Sell | Neutral | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 3.33 | 3.73 | 3.30 | -0.34 | -9.26% | 483.20K | NYSE | |||
| 591.86 | 606.40 | 587.41 | -19.86 | -3.25% | 961.72K | NYSE | |||
| 10.01 | 10.02 | 10.00 | -0.01 | -0.10% | 830.00 | NASDAQ | |||
| 43.13 | 45.28 | 42.29 | -5.34 | -11.02% | 7.93M | NYSE | |||
| 237.05 | 251.00 | 236.84 | -13.90 | -5.54% | 1.36M | NYSE | |||
| 43.50 | 43.85 | 43.15 | -0.07 | -0.16% | 651.95K | NASDAQ | |||
| 96.28 | 104.22 | 95.71 | -6.19 | -6.04% | 141.76M | NASDAQ | |||
| 18.48 | 19.12 | 18.20 | +0.22 | +1.20% | 343.41K | NYSE | |||
| 2.53 | 2.74 | 2.46 | -0.20 | -7.33% | 19.72M | NASDAQ | |||
| 9.785 | 9.79 | 9.785 | -0.005 | -0.05% | 6.33K | NASDAQ | |||
| 5.12 | 5.46 | 5.07 | -0.43 | -7.75% | 527.10K | NYSE | |||
| 9.83 | 9.83 | 9.83 | -0.03 | -0.30% | 14.00 | NASDAQ | |||
| 18.15 | 19.69 | 18.12 | -1.57 | -7.96% | 13.58M | NASDAQ | |||
| 3.18 | 3.47 | 3.14 | -0.20 | -5.92% | 771.33K | NYSE | |||
| 72.40 | 75.72 | 71.99 | -5.12 | -6.60% | 2.58M | NYSE |